Accordingly, AML cell lines (MV4-11 and MOLM-13) and primary AML patient cells which carry the FLT3-ITD or KIT mutation exhibited sensitivity to ROCK inhibitor DJ4 (Figure 1 and Figure 2). The gene discussed is FLT3; the disease is acute myeloid leukemia.